TRPC1 and non-small cell lung carcinoma: TRPC1 overexpression is linked with unfavorable DFS in patients receiving adjuvant chemotherapy, whereas TRPC1 expression is not correlated with DFS in those who do not receive adjuvant chemotherapy; a possible explanation could be that: patients receiving adjuvant chemotherapy are usually diagnosed with a more advanced TNM stage compared with those who do not receive adjuvant chemotherapy; thereby, the intercorrelation of TRPC1 with DFS might be amplified in NSCLC patients with the elevated TNM stage but minimized in NSCLC patients with declined TNM stage.